Squarepoint Ops LLC Boosts Stock Position in Personalis, Inc. (NASDAQ:PSNL)

Squarepoint Ops LLC raised its position in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 438.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 91,684 shares of the company's stock after purchasing an additional 74,664 shares during the quarter. Squarepoint Ops LLC owned 0.13% of Personalis worth $530,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Lightspeed Management Company L.L.C. purchased a new position in shares of Personalis during the 4th quarter valued at about $47,169,000. Blue Water Life Science Advisors LP lifted its holdings in Personalis by 13.3% in the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company's stock worth $6,548,000 after purchasing an additional 132,900 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Personalis by 144.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock worth $2,372,000 after purchasing an additional 242,141 shares in the last quarter. Jane Street Group LLC lifted its holdings in Personalis by 144.3% in the 4th quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock worth $2,320,000 after purchasing an additional 237,033 shares in the last quarter. Finally, abrdn plc purchased a new stake in shares of Personalis during the 4th quarter worth approximately $1,722,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Trading Up 3.0%

NASDAQ:PSNL traded up $0.15 during trading hours on Friday, hitting $5.21. The company had a trading volume of 741,165 shares, compared to its average volume of 1,029,015. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20. The company has a market cap of $460.17 million, a P/E ratio of -3.10 and a beta of 1.86. The company has a 50-day moving average of $4.13 and a 200 day moving average of $4.48.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. On average, analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright boosted their target price on Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 price target on shares of Personalis in a research report on Thursday, April 10th. Craig Hallum assumed coverage on Personalis in a research note on Monday, March 17th. They set a "buy" rating and a $8.00 price objective for the company. Finally, Guggenheim began coverage on Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $7.67.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.